OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Cancer is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)

Article	Citations
Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells	264
RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC	248
Reply to Comment on: ‘Hypoxia differently modulates the release of mitochondrial and nuclear DNA’	153
Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial	133
Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours	132
Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach	121
Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma	112
Patterns of incident Burkitt lymphoma during the HIV epidemic among the Black African and White population in South Africa	111
Treating tobacco dependency in cancer care: essential, cost-effective, and feasible, yet overlooked	109
Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom	107
GDP-bound Rab37 modulates M2-like tumor-associated macrophage polarization by attenuating STAT1 translocation to downregulate the type I IFN pathway	107
CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer	101
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts	99
Effects of cancer screening restart strategies after COVID-19 disruption	98
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer	94
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care	91
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression	89
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	85
An emerging role for BAG3 in gynaecological malignancies	81
C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer	81
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer	81
Chronic oxidative stress adaptation in head and neck cancer cells generates slow-cyclers with decreased tumour growth in vivo	80
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression	79
Statin use and survival among women with ovarian cancer: an Australian national data-linkage study	74
Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database	72

Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia	71
Advancing translational research for colorectal immuno-oncology	71
Liquid biopsy: creating opportunities in brain space	70
A spectroscopic liquid biopsy for the earlier detection of multiple cancer types	70
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	65
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	65
Correction: Maternal and childhood medical history and the risk of childhood brain tumours: a case–control study in Ontario, Canada	64
Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies	64
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases	62
Tertiary lymphoid structures correlate with enhancement of antitumor immunity in esophageal squamous cell carcinoma	62
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	62
Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy	62
Clinical impact of PET/MRI in oligometastatic colorectal cancer	61
Correction: How do women experience a false-positive test result from breast screening? A systematic review and thematic synthesis of qualitative studies	61
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	61
A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study	61
Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence	60
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience	59
Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80	58
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours	58
A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer	56
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	56
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	55
The cost-effectiveness of risk-stratified breast cancer screening in the UK	55
Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme	55
A taxonomy of early diagnosis research to guide study design and funding prioritisation	55
Associations between obesity, metabolic health, and the risk of breast cancer in East Asian women	54
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours	54
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit	53
SIRT1 is an actionable target to restore p53 function in HPV-associated cancer therapy	53
Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer	53
Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a case–control study	53